Analysts Issue Forecasts for Soligenix FY2025 Earnings

Soligenix, Inc. (NASDAQ:SNGX) – Equities research analysts at Zacks Small Cap cut their FY2025 earnings per share (EPS) estimates for Soligenix in a report released on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will post earnings of ($3.09) per share for the year, down from their prior forecast of ($2.93). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s FY2026 earnings at ($2.02) EPS.

Soligenix Price Performance

SNGX stock opened at $2.21 on Friday. Soligenix has a one year low of $1.83 and a one year high of $14.92. The stock has a market cap of $5.55 million, a price-to-earnings ratio of -0.29 and a beta of 2.03. The company has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $3.06.

Soligenix (NASDAQ:SNGX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.20 million. During the same period in the previous year, the firm posted ($12.66) earnings per share.

Institutional Trading of Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC raised its position in shares of Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the period. Geode Capital Management LLC owned approximately 1.04% of Soligenix worth $71,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.60% of the company’s stock.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.